For research and education only · Not reviewed by a medical professional · Disclaimer

← PepsRadar home

Research field guide

Mitochondrial peptides: what MOTS-c, humanin and SS-31 (elamipretide) actually show in people

Content updated · how dates work

MOTS-c and humanin are made by mitochondria; elamipretide (SS-31) is a drug aimed at them. Mouse data and blood-level studies back the first two; only elamipretide has human trials and a narrow FDA approval.

PepsRadar editorial · November 12, 2026 · Original, AI-assisted guide · Not reviewed by a medical professional

1 of 3: Only elamipretide has FDA approval, an accelerated one for Barth syndrome; MOTS-c and humanin have none.
01

Two different things share one label

"Mitochondrial peptide" gets used for two unrelated groups. Mitochondrial-derived peptides are made by the body itself: they are encoded by short stretches of DNA inside the mitochondria, and humanin and MOTS-c are the best-known examples. MOTS-c, described in 2015, is a 16-amino-acid peptide coded within a mitochondrial ribosomal RNA gene.

Elamipretide, also called SS-31, is something else: a synthetic four-amino-acid peptide that interacts with cardiolipin, a fat in the inner mitochondrial membrane. It is a drug designed to act on mitochondria, not a natural signal they release, and its evidence looks nothing like the other two.

Source: Fuku et al., Aging Cell 2015 ↗

Source: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. ↗

Source: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

02

MOTS-c: strong mouse data, human data mostly measurement

In mice, MOTS-c treatment prevented diet-induced obesity and insulin resistance linked to age and a high-fat diet. A 2021 study reported better physical performance in young, middle-aged and old mice, and more physical capacity and healthspan when treatment started late in life.

The human part of that 2021 study measured people's own MOTS-c: exercise raised it in muscle and blood. Nobody was given the peptide. Other human work is observational too. In an 85-person study, blood MOTS-c did not differ between people with obesity and people of normal weight; it fell with age and rose with insulin resistance. None of these is a randomized treatment trial in people (our MOTS-c and exercise guide covers that question in more depth).

Source: The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. ↗

Source: MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. ↗

Source: Ozkaya et al., Arch Endocrinol Metab 2025 ↗

03

Humanin: protective in cells, a mixed biomarker in people

Humanin was discovered in 2001 when it protected cultured nerve cells from death caused by several Alzheimer's-linked genes and amyloid-beta, though not from every insult tested. A 2009 rodent study found that humanin and stronger synthetic versions improved insulin sensitivity, and that circulating humanin declined with age in humans and mice.

Larger human data complicate that picture. Among 693 people aged 21 to 113, plasma humanin rose with age and was highest in centenarians, and higher levels went with worse measures such as weaker handgrip in 70-year-olds. A later study from the same group found humanin lower in Alzheimer's disease but not in type 2 diabetes. These studies measured humanin; none gave it to people.

Source: A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. ↗

Source: Humanin: a novel central regulator of peripheral insulin action. ↗

Source: Conte et al., J Gerontol A 2019 ↗

Source: Conte et al., GeroScience 2021 ↗

04

Elamipretide: real trials, mixed results

Elamipretide has been through placebo-controlled trials. In Barth syndrome, a rare genetic disorder of cardiolipin, the TAZPOWER trial randomized 12 people and met neither main goal (a six-minute walk test and a symptom score) in its blinded phase. In the open-label extension, 10 patients continued and 8 reached week 168, with walking distance improving and injection-site reactions the most common side effect. That phase had no placebo group for comparison.

Larger trials in other conditions missed their main goals. MMPOWER-3 randomized 218 adults with primary mitochondrial myopathy and found no improvement in walking distance or fatigue at 24 weeks, though the drug was well tolerated. PROGRESS-HF, in 71 people with heart failure, found no improvement in heart volume after four weeks.

Source: A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism. ↗

Source: Thompson et al., Genetics in Medicine 2024 (TAZPOWER extension) ↗

Source: Karaa et al., Neurology 2023 (MMPOWER-3) ↗

Source: Butler et al., J Card Fail 2020 (PROGRESS-HF) ↗

05

Where each stands with FDA and WADA

On September 19, 2025, FDA granted Forzinity (elamipretide) accelerated approval as the first treatment for Barth syndrome, to improve muscle strength. The decision rests on knee-extensor strength, a measure FDA judged reasonably likely to predict real benefit, and the company must run a confirmatory randomized, placebo-controlled trial. The approval does not cover "research" SS-31: FDA warning letters in August 2026 called SS-31 products from research-peptide sellers unapproved new drugs.

Neither MOTS-c nor humanin is FDA-approved. MOTS-c sat in FDA's 503A Category 2 (significant safety risks, including possible immunogenicity) until its nominations were withdrawn. On October 28, 2026, HHS said it would not act against licensed pharmacies or physicians compounding certain peptides, MOTS-c among them, while rulemaking proceeds; that is not approval. Humanin is not on FDA's 503A category lists. WADA's 2026 list names MOTS-c as a banned metabolic modulator, and humanin likely falls under its non-approved substances class.

Source: FDA press announcement, Sept 2025 ↗

Source: FDA warning letter, Aug 2026 ↗

Source: FDA 503A Category 2 safety-risk page ↗

Source: HHS enforcement discretion notice, Federal Register 2026 ↗

Source: FDA 503A bulk substance category lists ↗

Source: WADA 2026 Prohibited List ↗

06

Bottom line

Of the three, only elamipretide has controlled human trials and an FDA approval, and even that is narrow: one rare disease, an accelerated pathway still awaiting confirmation, and negative main results in larger trials elsewhere. MOTS-c and humanin are interesting natural signals, and researchers have proposed that raising their levels might help with aging, but the human evidence so far is mostly blood levels and associations.

PepsRadar gives no dosing or sourcing advice. Anyone weighing these compounds should talk with a licensed clinician.

Source: Shirley, Drugs 2026 (Elamipretide: First Approval) ↗

Source: Kim et al., GeroScience 2021 (review) ↗

Source: FDA press announcement, Sept 2025 ↗

Continue with the original research

Study examples are based on selected publication abstracts and the explicitly described source documents. This is not a systematic review or an individualized treatment guide. Editorial scope and methods.

See something wrong on this page? Report a mistake · Corrections